Based on the information provided, I was unable to find a specific frequency for adverse effect tests related to Lurbinectedin. However, Lurbinectedin is a drug that has been approved by the European Commission for the treatment of adult patients with certain types of relapsed or refractory small cell lung cancer (SCLC) [1].

Adverse effects of drugs, also known as side effects, can occur during or after treatment and can vary in severity. According to the European Medicines Agency (EMA), the most common adverse reactions of Lurbinectedin include neutropenia, nausea, fatigue, and increased levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [2].

It is important to note that the frequency of adverse effects can vary depending on several factors, such as the dose and duration of treatment, the patient's overall health, and other medications that the patient may be taking. Therefore, healthcare professionals should closely monitor patients receiving Lurbinectedin for any signs of adverse effects and adjust the treatment regimen accordingly.

In summary, while there is no specific frequency available for adverse effect tests related to Lurbinectedin, healthcare professionals should closely monitor patients receiving this drug for any signs of adverse effects.

Sources:

1. "Lurbinectedin recommended for approval in the EU for the treatment of small cell lung cancer." European Medicines Agency. <https://www.ema.europa.eu/en/news/lurbinectedin-recommended-approval-eu-treatment-small-cell-lung-cancer>.
2. "Lurbinectedin: Summary of product characteristics." European Medicines Agency. <https://www.ema.europa.eu/en/medicines/human/EPAR/zepzelca>.
3. "Lurbinectedin." DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/lurbinectedin>.